Due to the possibility of blocking tumor angiogenesis by acting on VEGF-A, pharmacological studies have led to the approval of a monoclonal antibody (mAb) against VEGF-A (bevacizumab/Avastin) in cancer therapy. This evidence concerns the gene VEGFA and neoplasm.